Dr. Cotter discusses allergic contact dermatitis, a skin condition with more than three million cases in the United States per year SCOTTSDALE, Ariz. – Feb. 19, 2021 – — Journey Medical Corporation (Journey Medical) today released a new Journey with the Experts video featuring David Cotter, MD, PhD, a board-certified dermatologist with Las Vegas Dermatology. Dr. Cotter discusses allergic contact dermatitis with Journey Medical, including what it is, why it occurs and how those affected can seek treatment from their local dermatology practice.Allergic contact dermatitis is a skin rash caused by contact with a certain substance. The substance might irritate the skin or trigger an allergic reaction. Some common culprits include soap, cosmetics, fragrances, jewelry and poison ivy. To view the Journey with the Experts video featuring Dr. Cotter, please visit https://vimeo.com/505494562/65a4bb2ab7.About Journey with the ExpertsJourney with the Experts is an educational initiative supported by Journey Medical Corporation, the medical dermatology company. The initiative is designed to educate the general public on common medical dermatology skin disorders and explain how these conditions can be treated at local dermatology practices.About Journey Medical CorporationJourney Medical is focused on identifying, acquiring and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model. The company currently markets five products that help treat and heal common skin conditions. The Journey Medical team is comprised of industry experts with extensive experience commercializing some of the most successful prescription dermatology brands. Journey Medical is located in Scottsdale, Arizona and is a partner company of Fortress Biotech, Inc. (NASDAQ:FBIO). For additional information about Journey Medical, visit https://journeymedicalcorp.com/.About David Cotter, MD, PhDAs a native Las Vegan, Dr. Cotter is excited and proud to practice dermatology in his hometown. Dr. Cotter graduated from the University of Nevada, Las Vegas (UNLV) with highest honors and obtained both an MD and a PhD in Molecular Cell Biology and Physiology from Washington University School of Medicine. As a scientist, Dr. Cotter discovered important ways the body uses nutrients. Specifically, he is an expert in ketone body metabolism and has spent years studying cardiovascular disease, diabetes and fatty liver disease. Dr. Cotter completed an internship in Internal Medicine at the UNLV School of Medicine in which he was named Intern of the Year. He then completed his dermatology residency at the University of California San Diego Medical Center. As a dermatologist, Dr. Cotter has trained with world leaders across the dermatology spectrum. Having presented at multiple national meetings and having published many peer reviewed articles, his unique background as a physician-scientist allows Dr. Cotter to offer his patients the most advanced skin care treatments. For additional information about Dr. Cotter, please visit https://lasvegasdermatology.com/dr-david-cotter/.Forward Looking StatementsThis press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “we”, “us” and “our” may refer to Fortress individually, a partner company individually, or Fortress together with one or more partner companies, as dictated by context. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; risks relating to the timing of starting and completing clinical trials; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law.